Gallery
Picture 1
Ntla stock forecast analysts’ NTLA stock forecast
New with box
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
Analysts’ NTLA stock forecast integrates biotech market trends, suggesting potential breakout if FDA fast-track designation arrives for NTLA- As many as 20 Wall Street analysts have an average “Strong Buy,” rating on Intellia stock, and the price target is $43.44, with the highest forecast of $91.00 and the lowest at $11.00, according to data from TipRanks. The average price forecast represents a 350.62% change from the last price of $9.64. Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on developing CRISPR-based therapies to address unmet medical needs. The company aims to revolutionize medicine by leveraging gene editing technology to create novel, first-in-class medicines, particularly in the field of transthyretin amyloidosis. NTLA stock forecast probabilities from quantitative models indicate a 60% chance of trading above $38 in the next 90 days, assuming no adverse regulatory headlines.